NEW YORK (GenomeWeb) – Italian diagnostics firm Diatech Pharmacogenetics is busy these days. The company, which sells more than a dozen diagnostic test kits for the precision oncology market, bills itself as the owner of more than 70 percent of the Italian molecular diagnostic market. Now, it wants a share of the global stool-sample colorectal cancer testing market, too.

Full article